Lucid Diagnostics
LUCD
23 hedge funds and large institutions have $2.6M invested in Lucid Diagnostics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1.08% less ownership
Funds ownership: 5.97% → 4.9% (-1.1%)
26% less capital invested
Capital invested by funds: $3.52M → $2.6M (-$919K)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$66.2K |
| 2 |
ACP
Arcus Capital Partners
Atlanta,
Georgia
|
+$5.58K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.37K |
| 4 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$2.7K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
-$405K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$90K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$54K |
| 4 |
LM
Luminus Management
Houston,
Texas
|
-$39K |
| 5 |
Morgan Stanley
New York
|
-$33K |
LUCD Hedge Fund Activity: Q4 2022 in Review
23 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Lucid Diagnostics (LUCD) for Q4 2022, worth a combined $2.6M — down 26% from $3.52M a quarter earlier.
Fund positioning in LUCD was balanced in Q4 2022: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 9 trimmed.
The largest buyer was Levin Capital Strategies, opening a new position worth an estimated $66.2K. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $405K sold.
- 23 institutional investors held Lucid Diagnostics (LUCD) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $2.6M of Lucid Diagnostics stock for Q4 2022, down 26% quarter-over-quarter.
- 4 funds opened new Lucid Diagnostics positions in Q4 2022 and 4 closed out, a net change of 0 holders.
- The largest Lucid Diagnostics buyer in Q4 2022 was Levin Capital Strategies, an estimated $66.2K added.
- The largest Lucid Diagnostics seller in Q4 2022 was Cantor Fitzgerald, an estimated $405K sold.
Based on aggregated 13F filings for Q4 2022.